Bank of New York Mellon’s ADMA Biologics ADMA Stock Holding History

Bank of New York Mellon’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.5M	Sell	1,250,658 -104,785	-8%	-$955K	﹤0.01%	2001
2026 Q1	$12.2M	Sell	1,355,443 -47,769	-3%	-$754K	﹤0.01%	1820
2025 Q4	$25.6M	Sell	1,403,212 -20,238	-1%	-$341K	﹤0.01%	1395
2025 Q3	$20.9M	Sell	1,423,450 -75,866	-5%	-$1.3M	﹤0.01%	1531
2025 Q2	$27.3M	Buy	1,499,316 +30,707	+2%	+$626K	0.01%	1352
2025 Q1	$29.1M	Sell	1,468,609 -52,557	-3%	-$909K	0.01%	1291
2024 Q4	$26.1M	Buy	1,521,166 +147,748	+11%	+$2.78M	﹤0.01%	1408
2024 Q3	$27.5M	Buy	1,373,418 +606,874	+79%	+$9.44M	0.01%	1400
2024 Q2	$8.57M	Buy	766,544 +49,631	+7%	+$416K	﹤0.01%	2039
2024 Q1	$4.73M	Sell	716,913 -62,989	-8%	-$344K	﹤0.01%	2355
2023 Q4	$3.53M	Sell	779,902 -25,798	-3%	-$95.4K	﹤0.01%	2542
2023 Q3	$2.88M	Buy	805,700 +16,551	+2%	+$63.7K	﹤0.01%	2595
2023 Q2	$2.91M	Buy	789,149 +113,341	+17%	+$420K	﹤0.01%	2625
2023 Q1	$2.24M	Buy	675,808 +27,928	+4%	+$96.5K	﹤0.01%	2739
2022 Q4	$2.51M	Buy	647,880 +67,053	+12%	+$207K	﹤0.01%	2724
2022 Q3	$1.41M	Buy	580,827 +81,017	+16%	+$194K	﹤0.01%	3037
2022 Q2	$990K	Buy	499,810 +416,409	+499%	+$819K	﹤0.01%	3217
2022 Q1	$153K	Buy	83,401 +36,967	+80%	+$57.7K	﹤0.01%	4314
2021 Q4	$65K	Hold	46,434	–	–	﹤0.01%	4462
2021 Q3	$52K	Sell	46,434 -13,316	-22%	-$18.7K	﹤0.01%	4432
2021 Q2	$96K	Sell	59,750 -145,662	-71%	-$256K	﹤0.01%	4224
2021 Q1	$362K	Sell	205,412 -3,363	-2%	-$7.7K	﹤0.01%	3840
2020 Q4	$406K	Buy	208,775 +14,953	+8%	+$31.4K	﹤0.01%	3715
2020 Q3	$463K	Sell	193,822 -23,015	-11%	-$63.1K	﹤0.01%	3528
2020 Q2	$635K	Buy	216,837 +23,183	+12%	+$66.6K	﹤0.01%	3355
2020 Q1	$558K	Buy	193,654 +32,001	+20%	+$111K	﹤0.01%	3307
2019 Q4	$647K	Buy	161,653 +27,901	+21%	+$122K	﹤0.01%	3458
2019 Q3	$595K	Buy	133,752 +51,576	+63%	+$216K	﹤0.01%	3439
2019 Q2	$317K	Buy	82,176 +21,545	+36%	+$95.1K	﹤0.01%	3792
2019 Q1	$230K	Buy	60,631 +5,803	+11%	+$20.5K	﹤0.01%	3837
2018 Q4	$131K	Hold	54,828	–	–	﹤0.01%	3924
2018 Q3	$340K	Hold	54,828	–	–	﹤0.01%	3789
2018 Q2	$247K	Buy	54,828 +35,791	+188%	+$178K	﹤0.01%	3875
2018 Q1	$87K	Buy	+19,037	New	+$75.7K	﹤0.01%	4087
2017 Q4	–	Sell	-21,344	Closed	-$66K	–	4354
2017 Q3	$66K	Hold	21,344	–	–	﹤0.01%	4059
2017 Q2	$79K	Buy	+21,344	New	+$85.7K	﹤0.01%	4066

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return

MCM

Marathon Capital Management Hunt Valley, Maryland $494M AUM 42.6% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon's ADMA Position: Q2 2026 in Review

Bank of New York Mellon reduced its ADMA Biologics (ADMA) stake by 7.7% in Q2 2026, selling an estimated $955K and leaving 1,250,658 shares worth $10.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2001.

Bank of New York Mellon first reported a position in ADMA in Q2 2017 and has held it in 36 quarters since. The position peaked at $29.1M in Q1 2025. 140 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Bank of New York Mellon held 1,250,658 shares of ADMA Biologics worth $10.5M as of Q2 2026.
Bank of New York Mellon sold 104,785 ADMA Biologics shares in Q2 2026, an estimated $955K.
ADMA Biologics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2001 holding.
Bank of New York Mellon first reported a position in ADMA Biologics in Q2 2017 and has held it in 36 quarters since.
Bank of New York Mellon's ADMA Biologics position peaked at $29.1M in Q1 2025.
140 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.